KR950032157A - 보호된 아미노티아졸릴아세트산 유도체 - Google Patents

보호된 아미노티아졸릴아세트산 유도체 Download PDF

Info

Publication number
KR950032157A
KR950032157A KR1019950006873A KR19950006873A KR950032157A KR 950032157 A KR950032157 A KR 950032157A KR 1019950006873 A KR1019950006873 A KR 1019950006873A KR 19950006873 A KR19950006873 A KR 19950006873A KR 950032157 A KR950032157 A KR 950032157A
Authority
KR
South Korea
Prior art keywords
group
acetic acid
general formula
lower alkoxy
salt
Prior art date
Application number
KR1019950006873A
Other languages
English (en)
Inventor
요시오 우라와
아끼히꼬 시모따니
다께오 가나이
마사히꼬 쯔지
Original Assignee
고니시 마사유끼
에이자이 가가꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고니시 마사유끼, 에이자이 가가꾸 가부시끼가이샤 filed Critical 고니시 마사유끼
Publication of KR950032157A publication Critical patent/KR950032157A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

하기 일본식(I)의 보호된 아미노티아졸릴아세트산 유도체 또는 그의 염
(상기 식에서, A는 질소 원자 또는 메틴기이고;R1및 R2는 동리하거나 상이하며 각각 수소 원자, 저급 알킬기 또는 치환되거나 비치환된 아릴기이며;R3는 저급알콕시기, 할로겐화 저급 알콕시기, 트리페닐메톡시기, 저급 알킬기 또는 아실옥시기이고;R4는 할로겐 원자, 히드록실기, 저급알콕시기 또는 치환되거나 비치환된 아미노기이다); 및 그들의 제조 방법이 기재되어 있다. 본 발명에 따른 보호된 아미노티아졸릴아세트산 유도체는 세펨 골격 내로 2-(2-아미노트아졸-4-일)-2-알콕시이미노아세틸기 또는 2-(2-아미노티아졸-4-일)-2-알케노일기를 도입시키는데 유용한 중간체이다.

Description

보호된 아미노티아졸릴아세트산 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 하기 일반식(I)의 보호된 아미노티아졸릴아세트산 유도체 또는 그의 염.
    상기 식에서, A는 질소 원자 또는 메틴기이고;R1및 R2는 동일하거나 상이하며 각각 수소 원자, 저급 알킬기 또는 치환되거나 비치환된 아릴기이며;R3는 저급 알콕시기, 할로겐화 저급 알콕시기, 트리페닐메톡시기, 저급 알킬기 또는 아실옥시기이고;R4는 할로겐 원자, 히드록시기, 저급 알콕시기 또는 치환되거나 비치환된 아미노기이다.
  2. 하기 일반식(Ⅱ)의 아니노티아졸릴아세트산 유도체 또는 그의 염을 하기 일반식(Ⅲ)의 (할로겐화 메틸렌) 디알킬암모늄 할라이드와 반응시키는 것으로 이루어진, 제1항에 따른 보호된 아미노티아졸릴아세트산 유도체 또는 그의 염의 제조 방법.
    상기 식에서, A,R1,R2,R3및 R4는 제1항에서 정의한 바와 같으며;X는 할로겐 원자이다.
  3. 하기 일반식(Ⅱ)의 아미노티아졸릴아세트산 유도체 또는 그의 염을 하기 일반식(Ⅳ)의 포름아미드 유도체와, 옥시염화인, 포스겐, 디포시겐, 트리포스겐 또는 옥살릴 클로라이드로부터 선택된 염소화제의 액상 혼합물 중에서 반응시키는 것으로 이루어진, 제1항에 따른 보호된 아미노티아졸릴아세트산 유도체 또는 그의 염의 제조 방법.
    상기 식에서, A,R1,R2,R3및 R4는 제1항에서 정의한 바와 같다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950006873A 1994-03-30 1995-03-29 보호된 아미노티아졸릴아세트산 유도체 KR950032157A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP94-82619 1994-03-30
JP8261994 1994-03-30
JP94-139918 1994-06-22
JP13991894 1994-06-22
JP94-283543 1994-11-17
JP6283543A JPH0867676A (ja) 1994-03-30 1994-11-17 保護アミノチアゾリル酢酸誘導体

Publications (1)

Publication Number Publication Date
KR950032157A true KR950032157A (ko) 1995-12-20

Family

ID=27303972

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950006873A KR950032157A (ko) 1994-03-30 1995-03-29 보호된 아미노티아졸릴아세트산 유도체

Country Status (7)

Country Link
US (3) US5665888A (ko)
EP (1) EP0675116B1 (ko)
JP (1) JPH0867676A (ko)
KR (1) KR950032157A (ko)
CN (1) CN1056371C (ko)
CA (1) CA2145012A1 (ko)
DE (1) DE69502982T2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812549B1 (fr) * 2000-08-03 2003-03-21 Aventis Pharma Sa Associations dalfopristine/quinupristine avec le cefpirome
US20100083415A1 (en) * 2008-10-07 2010-04-08 Dawn Beckford Driver arm shade
CN107987091A (zh) * 2017-11-07 2018-05-04 河北九派制药股份有限公司 一种盐酸头孢替安杂质3-甲基头孢替安盐酸盐的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3145727A1 (de) * 1981-11-19 1983-05-26 Bayer Ag, 5090 Leverkusen Zwischenprodukte, verfahren zu deren herstellung und verfahren zur herstellung von cephalosporinen
ATE30724T1 (de) * 1982-06-28 1987-11-15 Bristol Myers Co Cephalosporinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten.
US4525473A (en) * 1983-03-30 1985-06-25 Bristol-Myers Company Cephalosporins
JPS6153272A (ja) * 1984-08-24 1986-03-17 Shionogi & Co Ltd グルタル酸誘導体の製法
US4652644A (en) * 1985-04-29 1987-03-24 Bristol-Myers Company Process for preparation of N7 -amidino substituted mitomycin C derivatives
EP0210815A3 (en) * 1985-07-25 1988-04-20 Beecham Group Plc 6-beta-(alpha-etherified oxyimino)-acylamino penicillanic-acid derivatives, their preparation and use

Also Published As

Publication number Publication date
JPH0867676A (ja) 1996-03-12
EP0675116B1 (en) 1998-06-17
EP0675116A1 (en) 1995-10-04
DE69502982T2 (de) 1998-12-10
CN1114315A (zh) 1996-01-03
US5665888A (en) 1997-09-09
CA2145012A1 (en) 1995-10-01
US5650518A (en) 1997-07-22
CN1056371C (zh) 2000-09-13
US5631378A (en) 1997-05-20
DE69502982D1 (de) 1998-07-23

Similar Documents

Publication Publication Date Title
KR880002823A (ko) 약제학적 화합물
KR850005829A (ko) 2-시아노벤즈이미다졸 유도체의 제조방법
KR920000766A (ko) 4급 암모늄 치환 프로페닐기를 제3위치에 함유하는 세팔로스포린류, 이들의 제조방법, 이들의 의약으로서의 용도, 이들을 함유하는 조성물 및 중간체
KR860000243A (ko) 아민유도체의 제조방법
KR840002358A (ko) 알파 2-길항작용을 일으키는 약제조성물 및 그 방법
KR860001065A (ko) 4-아세톡시-3-히드록시에틸아제티진-2-온유도체의 제조방법
KR950032157A (ko) 보호된 아미노티아졸릴아세트산 유도체
KR840006009A (ko) 티에노 피리미딘 유도체 및 이의 산부가염의 제조방법
KR850005845A (ko) 7-아미노-3-치환된-메틸-3-세펨-4-카복실산 및 그의 저급 알킬실릴 유도체의 제조방법
KR890005142A (ko) 17-치환된 안드로스타-1,4-디엔-3-온 유도체
KR860003259A (ko) 벤젠-융합 복소환 화합물의 제조방법
KR850002260A (ko) 치환된 4-알킬-2(1h) 퀴나졸린온-1-알카노산 유도체의 제조방법
KR890017258A (ko) 신규 세팔로스포린 유도체 및 그의 제조방법
KR860003202A (ko) 요오드 트리아미노벤젠 화합물의 제조방법
KR840002821A (ko) N-(2,3-에폭시프로필렌)-n-아르알킬술폰아미드 유도체의 제조방법
KR840008647A (ko) 대칭 1,4-디하이드로피리딘디카복실 에스테르의 제조방법
KR930021632A (ko) 벤조[b]티오펜-5-일 유도체 및 이의 제조방법
KR900018011A (ko) 무수 매질중에서의 아실 시아나이드의 제조방법
KR830004211A (ko) N-(2,2-디알콕시에틸)-n-치환된-2,2-디클로로 아세트아미드의 제조방법
KR850007800A (ko) 세팔로스포린 유도체의 에스테르 제조방법
KR830006293A (ko) 신규 폴리아자 헤테로고리 화합물의 제조방법
KR840006999A (ko) 치환된 트로필 및 슈도트로필 벤조에이트의 제조방법
KR870002110A (ko) 구아니디노티아졸 유도체의 제조방법
KR850004581A (ko) α,α-디메틸페닐아세트아닐리드 유도체의 제조방법
KR840004093A (ko) 3,4-디하이드로-2h-1,2-벤조티아진-카복실산-1,1-디옥사이드류의 제조방법

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application